NCT03243617已完成不适用
A Placebo-Controlled, Double-Blind, Bi-Lateral Study to Evaluate the Performance and Tolerability of a Cosmetic Product Designed to Improve the Appearance of Skin Afflicted With Keratosis Pilaris
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AOBiome LLC
- 入组人数
- 26
- 试验地点
- 2
- 主要终点
- Number of Participants With Treatment-Related Adverse Events as assessed by physical exam and appearance
研究概览
简要总结
The purpose of this study is to demonstrate the safety, tolerability and efficacy of AO+ Mist administered daily for 4 weeks to improve the appearance of skin afflicted with keratosis pilaris.
详细描述
This will be a single center, double-blind, placebo-controlled study in subjects with keratosis pilaris affecting both sides of the body.
Subjects will be screened within 4 weeks of enrollment. Subjects will be seen at the research facility on for the baseline visit and will be asked to return to the site on weeks 1, 2, 3 and 4 for assessments. Test product application will occur for four weeks starting with the day of the baseline visit.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Double (Participant, Care Provider)
盲法说明
AO+ Mist (or placebo) are supplied in white 100mL metered spray bottles. Test products are blinded and labeled for application to the LEFT or RIGHT side of the body.
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female subjects ≥18 and ≤65 years of age
- •Subject is in good general health
- •Diagnosis of keratosis pilaris involving areas of the body affected bilaterally
- •Subject has Fitzpatrick Skin Type I-VI
- •Willing to refrain from using any treatments, other than the investigational product, including antibiotics, for acne present on the face.
- •Ability to comprehend and comply with procedures
- •Agree to commit to participate in the current protocol
- •Provide written informed consent prior to any study procedure being performed (all subjects should be able to understand the informed consent form and any other documents that subjects are required to read)
排除标准
- •Male and female subjects under 18 years or over 65 years of age
- •Female subjects who are pregnant or lactating
- •Subjects who have received laser therapy to the KP affected area in the past 1 year
- •Subjects with a concurrent diagnosis of another skin condition or malignancy
- •Subjects with tan or sunburn over the area affected by KPin the past month
- •Subjects with open, non-healing sores or infections at any skin site
- •Treatment with over-the-counter topical medications for the treatment of acne vulgaris including benzoyl peroxide, topical anti-inflammatory medications, corticosteroids, α-hydroxy/glycolic acid, including lactic acid lotions (Am-Lactin, Lac-Hydrin), urea cream (Carmol 10, Carmol 20, Carmol 40, Urix 40), salicylic acid (Salex lotion), topical corticosteroids within 4 weeks prior to baseline.
- •Treatment with systemic corticosteroids (including intranasal and inhaled corticosteroids) within 4 weeks prior to baseline
- •Treatment with systemic antibiotics or systemic anti-acne drugs or systemic anti-inflammatory drugs within 4 weeks prior to baseline
- •Prescription topical retinoid use on the face or body within 4 weeks of baseline (e.g., tretinoin, tazarotene, adapalene).
- •Oral retinoid use (e.g., isotretinoin) within 12 months prior to baseline or vitamin A supplements greater than 10,000 units/day within 6 months of baseline..
- •Treatment with any investigational drug within 30 days prior to the beginning of the screening period (this includes investigational formulations of marketed products, inhaled and topical drugs)
- •Subjects who are unable to understand the protocol or give informed consent
- •Any other condition and/or situation that causes the Investigator to deem a subject unsuitable for the study (e.g., due to expected study medication non-compliance, inability to medically tolerate the study procedures, or a subject's unwillingness to comply with study-related procedures)
结局指标
主要结局
Number of Participants With Treatment-Related Adverse Events as assessed by physical exam and appearance
时间窗: Baseline-Week 4
次要结局
- Difference in Keratosis pilaris Investigator Score(Baseline-Week 4)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
A Pilot Study of Oxaloacetate in Subjects With Treated PDParkinson's DiseaseNCT01741701University of Kansas Medical Center33
已完成
2 期
Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel SyndromeIrritable Bowel SyndromeNCT00583128Ocera Therapeutics117
已完成
3 期
Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With FistulasIntestinal FistulaInflammatory Bowel DiseaseNCT00321412Ocera Therapeutics191
进行中（未招募）
3 期
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)Epidermolysis BullosaNCT05838092RHEACELL GmbH & Co. KG9
进行中（未招募）
3 期
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over)Epidermolysis BullosaNCT05464381RHEACELL GmbH & Co. KG91